Advancing Life Sciences

Precision biology,
real-world impact.

Helixon US Inc is a biotechnology company committed to developing next-generation antibody therapeutics. We utilize novel pipelines and platforms that enable rapid discovery of candidates against targets often avoided by others due to their complexity. Our mindset is to embrace biologic challenges so we can provide patients with better therapeutic options.

Our Process Learn More

IgG

Conventional full-length antibody · ~150 kDa

VHH (Nanobody)

Single heavy-chain variable domain · Camelid-derived

IgNAR

Immunoglobulin new antigen receptor · Elasmobranch

About Us

Science-led, patient-driven

Helixon US Inc was founded on the belief that combining curiosity-driven science with rigorous evaluation is the best path to discovering breakthrough therapies. Our multidisciplinary team brings together decades of expertise in molecular biology, biochemistry, structural biology, immunology, cancer physiology, and virology. By further augmenting our skill set with the power of novel artificial intelligence, our goal is to move discoveries from bench to bedside with speed and precision.

Our Team

Nicholas Wu

PhD

Consultant
Associate Professor, University of Illinois Urbana-Champaign

Adam Nelczyk

PhD

Senior Scientist
Head of Assay Development

What We Do

Our Process

Target Selection

We focus on known drivers of disease with few, low efficacy, or no approved therapies — addressing treatment gaps where patients need options most.

Antibody Discovery

Our team utilizes proprietary natural and synthetic libraries to maximize an initial pool of high-value candidates.

Physiologic Screening

Screening on artificial materials doesn't save time when it inappropriately indicates target engagement. We avoid this by leveraging a novel, sensitive high-throughput approach that preserves a target's natural context.

Functional Validation

Binding isn't enough. We put our candidates through rigorous evaluations to ensure functional activity before advancing them further.

Get In Touch

Let's connect

Whether you're a potential partner, investor, or scientific collaborator, we'd love to hear from you.

Send Message

Precision biology,real-world impact.